Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 3Phase 1 3Phase 3 2Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7Lymphoid 3Thoracic 2Other solid neoplasm 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Neutropenia 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 10human papillomavirus vaccine, L1 type 16, 18 7olaparib 4niraparib 4Human Papillomavirus Recombinant Vaccine nonavalent 4Vaccines 3Saline Solution 3Papillomavirus Vaccines 3Medroxyprogesterone Acetate 3Carboplatin 3Bevacizumab 3pegylated granulocyte colony-stimulating factor 2liposomal doxorubicin 2fluciclovine F-18 2apatinib 2Sevoflurane 2Propofol 2Paclitaxel 2Aspirin 2semaglutide 1pegfilgrastim 1pazopanib 1palbociclib 1lenvatinib 1halofantrine 1ganirelix 1gadofosveset trisodium 1fosaprepitant 1follicle stimulating hormone, human, with HCG C-terminal peptide 1ferrous gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × pegfilgrastim × Gynecologic × Clear all
NCT00277160 2010-10-08

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Amgen

Phase 4 Completed
852 enrolled
BreastGynecologicLymphoidThoracic

Breast Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neutropenia, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡